Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (7): 831-840.doi: 10.12092/j.issn.1009-2501.2024.07.014

Previous Articles    

Research progress on material basis and mechanism of Hedyotis Diffusa-Scutellaria Barbata Herb Pair in the treatment of gastric cancer

ZHANG Xiaowei1, WANG Nan1, DAI Mengge1, LIU Ruijuan2, MA Ting1   

  1. 1 School of Pharmacy, Zhengzhou University, Zhengzhou 450001, Henan, China; 2 Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
  • Received:2024-02-26 Revised:2024-04-04 Online:2024-07-26 Published:2024-06-24

Abstract:

Gastric cancer is one of the most common malignant tumors in the digestive system, which often occurs in middle-aged and elderly people. Traditional Chinese medicine recognizes gastric cancer as a kind of tumor characterized by fluid deficiency, heat accumulation and the growing binding of toxins in the stomach. It is commonly treated with heat-clearing and detoxifying drugs in clinical practice. Hedyotis diffusa-Scutellaria barbata herb pair (HS) has the effects of clearing heat and detoxifying, promoting blood circulation, resolving carbuncle and expulsing boil, anti-inflammatory and analgesic, which are consistent with the etiology and pathogenesis of gastric cancer, therefore, it can be used for the treatment of gastric cancer. Modern pharmacological researches have confirmed that HS can play an anti-gastric cancer role by inducing cell apoptosis, inhibiting cell proliferation, inhibiting angiogenesis, improving immune microenvironment and down-regulating telomerase activity. Herein, this review summarizes the active ingredients and related mechanism responsible for the anti-gastric cancer effect of HS, which will provide the theoretical basis for its clinical use and the development of new drugs against gastric cancers.

Key words: Hedyotis diffusa, Scutellaria barbata, drug pair, gastric cancer, pharmacological mechanism

CLC Number: